Axsome Therapeutics, Inc. develops treatments for central nervous system (CNS) conditions, including depression, agitation associated with Alzheimer's disease, migraine, narcolepsy, and fibromyalgia. The company is advancing a pipeline of products, including AXS-05, AXS-12, and AXS-14, aimed at addressing these conditions.
